Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | OGG1 | O15527 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22480033 | 0.87 | AR (0.42) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22480124 | 0.87 | L3MBTL1 (0.46) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL21854432 | 0.86 | PTGS2 (0.44) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22480005 | 0.86 | AR (0.42) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22479966 | 0.85 | AR (0.41) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22480006 | 0.85 | AR (0.49) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22480026 | 0.84 | AR (0.45) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22479957 | 0.83 | AR (0.42) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22480023 | 0.83 | KDM4E (0.41) | ALDH1A1ARKDM4EMEN1KMT2A | |
| SCHEMBL22480022 | 0.82 | GRIN1 (0.46) | ALDH1A1ARKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684633-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113195441-B | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-12-01 | — | — | US | disclosed |
| CN-113195441-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| WO-2020081999-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | WO | disclosed |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | US | disclosed |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | US | disclosed |
| WO-2020081999-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | ALDH1A1 758/4885OGG1 3584/4885AR 1/4885 |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | ALDH1A1 758/4885OGG1 3584/4885AR 1/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | ALDH1A1 758/4885OGG1 3584/4885AR 1/4885 |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | ALDH1A1 758/4885OGG1 3584/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.